Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Optimizing blinatumomab for B-ALL

Rachel Rau • 31 Aug 2021
SOHO 2021
Acute Lymphoblastic Leukemia General Leukemia Antibodies Blinatumomab
AALL1731

Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, discusses the optimal use of blinatumomab for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), commenting on how it could be used to achieve undetectable measurable residual disease (MRD). Dr Rau also talks on the Phase III AALL1731 trial (NCT03914625) currently investigating blinatumomab in combination with chemotherapy for newly diagnosed (B-ALL). This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Disclosures

Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.

More from Rachel Rau

Updates on BiTEs for B-ALL 4:24
Updates on BiTEs for B-ALL
Rachel Rau • 31 Aug 2021
The importance of optimizing treatment of B-ALL at induction 1:33
The importance of optimizing treatment of B-ALL at induction
Rachel Rau • 31 Aug 2021
B-ALL patient selection for treatment with blinatumomab 3:04
B-ALL patient selection for treatment with blinatumomab
Rachel Rau • 31 Aug 2021

Related Videos

Evaluation of real-world ventoclax initiation prophylaxis & monitoring outcomes in patients with CLL 2:31
Evaluation of real-world ventoclax initiation prophylaxis & monitoring outcomes in patients with CLL
Nilanjan Ghosh • 10 Dec 2025
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study 1:41
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study
Inhye Ahn • 6 Dec 2025
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study 2:30
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Naval Daver • 8 Dec 2025
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
The content of VJHemOnc is intended for healthcare professionals